Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET
Company Participants
Werner Lanthaler - Chief Executive Officer
Enno Spillner - Chief Financial Officer
Craig Johnstone - Chief Operating Officer
Cord Dohrmann - Chief Scientific Officer
Matthias Evers - Chief Business Officer
Conference Call Participants
Zoe Karamanoli - RBC Capital Markets
Christian Ehmann - Warburg Research
James Quigley - Morgan Stanley
Derik de Bruin - Bank of America
Peter Welford - Jefferies
Joe Hedden - Rx Securities
Steven Mah - Cowen
Falko Friedrichs - Deutsche Bank
Victoria English - Evernow Publishing Limited
Werner Lanthaler
Good morning, good afternoon. Welcome from Evotec. Welcome to our Q9 presentation for Together for medicines that matter.
We have uploaded the presentation that is accompanying this call to our website, and you can follow this call throughout the next couple of quarters. When you go to Page 2 of this presentation. You can see that I'm here together with my team, our CFO, Enno; our COO, Craig; our CSO, Cord; and our CBO, Matthias. Enno and I will guide you through the initial report, and then we are all looking forward to your questions and are happy to answer that.
As you know, this call follows our second Capital Markets Day of 2022, which we had last week in Redmond and which was focused more or less only on Just - Evotec Biologics. So we are very happy to today give you a broader picture about the whole business ongoing in the group. And we will also, at this point of time, of course, refer to Just - Evotec Biologics. But if you have more detailed questions to Just, let me please also advise you to go to the Internet where we have now uploaded the webcast of this presentation and where you can really follow this Capital Markets Day.
Let me also thank you very much for attending this Capital Markets Day and your excellent questions around this.
So let's go into our business, and let's go into Page number 4. And let's look at the latest highlights and also lowlights of the nine months report of 2022. We are focused on execution, acceleration and it's fantastic to see that we see undisrupted demand in all sectors of our business. This is best reflected by new and extended discovery and development agreements and also highlighted by some so far smaller milestones, but milestones are coming in.